Close on the heels of a reasonably successful patent challenge by the German pharma Multinational Corporation (MNC) Fresenius Kabi for the breast cancer drug Tykerb of GlaxoSmithKline (GSK) in India, another MNC Mylan, with its headquarter in the United states, … Continue reading
Tag Archives: Brazil
India, China Revoke Four Pharma Patents in A Fortnight: A Double Whammy for MNCs?
Revocation of four pharma patents by India and China within a fortnight has raised many eyebrows, yet again, across the globe. In this short period, India has revoked three patents and China one. While this quick development is probably a … Continue reading
Balancing IPR with Public Health Interest: Brickbats, Power Play and Bouquets
It is now a widely accepted dictum that Intellectual Property Rights (IPR), especially pharma patents, help fostering innovation and is critical in meeting unmet needs of the patients. However, the moot question still remains, what type pharmaceutical invention, should deserve … Continue reading
A Force Multiplier: An “Armageddon”: A Contender for Supremacy in the Generic Pharma World
It is very important for any country to ensure access to most appropriate medicines for the patients as and when they require. In many disease areas such access can be remarkably improved through affordable generic drugs, which offer significant savings … Continue reading